
    
      The objective of this meta-analysis is to compare the incidence of malignancy (excluding
      non-melanomatous skin cancers) reported as serious adverse events in the ADOPT and RECORD
      studies between subjects randomly allocated to treatment with metformin with those allocated
      to rosiglitazone.
    
  